Injectable microfoam containing a sclerosing agent

• US RE38,919 E1
• Filed: 06/11/2003
• Issued: 12/13/2005
• Est. Priority Date: 06/23/1993
• Status: Expired due to Term

• Current Assignee: BTG International Limited (Boston Scientific Corporation)
• Original Assignee: BTG International Limited (Boston Scientific Corporation)
• Inventors: Garrido, Juan Cabrera, Garcia-Olmedo, Juan Cabrera
• Primary Examiner(s): VENKAT, JYOTHSNA A
• Application Number:
  US10/458,806
• Time in Patent Office: 916 Days
• Field of Search: 424/423, 424/484, 424/422, 424/424, 424/425, 604/82.C, 604/507
• US Class Current: 424/423
• CPC Class Codes: A61K 9/122 Foams; Dry foams edible foams A61K9/0056
• CPC Class Codes: Y10S 424/07 Microporous membranes
• CPC Class Codes: Y10S 514/945 Foam

Abstract

Injectable microfoam for sclerotcraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.

Claims

1. Prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.

2. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is polydocanol.

3. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is sodium tetradecyl sulfate.

4. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is a hypertonic glucostated by glucosaline solution.

5. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is chromated glycerol.

6. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is ethanolamine oleate.

7. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is sodium morrhuate.

8. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is any iodated solution.

9. A method for phlebologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.

10. A method for phlebologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.

11. A method for phlebologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.

12. A method for treatment of esophageal varices comprising injecting the microfoam of claim 1 into vessels to be treated.

13. A method for treatment of esophageal varices comprising injecting the microfoam of claim 2 into vessels to be treated.

14. A method for treatment of esophageal varices comprising injecting the microfoam of claim 3 into vessels to be treated.

15. A method for proctologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.

16. A method for proctologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.

17. A method for proctologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.

18. A method for angiologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.

19. A method for angiologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.

20. A method for angiologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.

21. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising

at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and

wherein the injectable microfoam is made in a container under pressure of oxygen.

22. The injectable microfoam of claim 21, wherein the at least one sclerosing substance is polidocanol.

23. The injectable microfoam of claim 21, wherein the microfoam further comprises at least one substance with a foaming capacity.

24. The injectable microfoam of claim 23, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.

25. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising

at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and

wherein the injectable microfoam is made in a container under pressure of a mixture of oxygen and carbon dioxide.

26. The injectable microfoam of claim 25, wherein the at least one sclerosing substance is polidocanol.

27. The injectable microfoam of claim 25, wherein the microfoam further comprises at least one substance with a foaming capacity.

28. The injectable microfoam of claim 27, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.

29. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising

at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and

wherein the injectable microfoam is made under pressure of oxygen in a hermetic container.

30. The injectable microfoam of claim 29, wherein the at least one sclerosing substance is polidocanol.

31. The injectable microfoam of claim 29, wherein the microfoam further comprises at least one substance with a foaming capacity.

32. The injectable microfoam of claim 31, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.

33. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising

at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and

wherein the injectable microfoam is made under pressure of a mixture of oxygen and carbon dioxide in a hermetic container.

34. The injectable microfoam of claim 33, wherein the at least one sclerosing substance is polidocanol.

35. The injectable microfoam of claim 33, wherein the microfoam further comprises at least one substance with a foaming capacity.

36. The injectable microfoam of claim 35, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.